[Brexucabtagene autoleucel (acute lymphatic r/r B cell leukemia, from 26 years of age) - Assessment according to §35a SGB V (1), Sentence 11]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004287
Original Title: Brexucabtagen-Autoleucel (akute lymphatische r/r B-Zell-Leukaemie, ab 26 Jahren)
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Antineoplastic Agents, Immunological
  • Immunotherapy, Adoptive
  • Receptors, Chimeric Antigen
  • Brexucabtagene Autoleucel
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Health Care Costs
  • Epidemiology
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.